A significantly higher risk of heart failure hospitalization associated with short-term rather than long-term use of sitagliptin (Table 2) was contradictory to the finding in the meta-analysis by Savarese et al. [6], which showed a significantly higher risk associated with long-term use of DPP-4 inhibitors for 29 weeks or more. This evidence concerns the gene DPP4 and heart failure.